BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, December 8, 2025
Breaking News: Trump administration impacts continue to roil the life sciences sector
See today's BioWorld Science
Home
» ALX-2004 exerts antitumor activity in EGFR-expressing tumors
To read the full story,
subscribe
or
sign in
.
Cancer
ALX-2004 exerts antitumor activity in EGFR-expressing tumors
Oct. 30, 2025
No Comments
ALX Oncology Inc. has developed ALX-2004, an antibody-drug conjugate (ADC) targeting epidermal growth factor receptor (EGFR) with a topoisomerase I inhibitor payload, for treating EGFR+ cancer solid tumors.
BioWorld Science
Conferences
AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics
Cancer
Antibody-drug conjugate
